These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 12406644)
1. CYP2C9 allelic variants: ethnic distribution and functional significance. Xie HG; Prasad HC; Kim RB; Stein CM Adv Drug Deliv Rev; 2002 Nov; 54(10):1257-70. PubMed ID: 12406644 [TBL] [Abstract][Full Text] [Related]
2. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Yang JQ; Morin S; Verstuyft C; Fan LA; Zhang Y; Xu CD; Barbu V; Funck-Brentano C; Jaillon P; Becquemont L Fundam Clin Pharmacol; 2003 Jun; 17(3):373-6. PubMed ID: 12803577 [TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484 [TBL] [Abstract][Full Text] [Related]
4. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Yasar U; Aklillu E; Canaparo R; Sandberg M; Sayi J; Roh HK; Wennerholm A Eur J Clin Pharmacol; 2002 Nov; 58(8):555-8. PubMed ID: 12451434 [TBL] [Abstract][Full Text] [Related]
5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220 [TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Lee CR; Goldstein JA; Pieper JA Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841 [TBL] [Abstract][Full Text] [Related]
7. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Muszkat M Clin Pharmacol Ther; 2007 Aug; 82(2):215-8. PubMed ID: 17329986 [TBL] [Abstract][Full Text] [Related]
8. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051 [TBL] [Abstract][Full Text] [Related]
9. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390 [TBL] [Abstract][Full Text] [Related]
10. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. Kudzi W; Dodoo AN; Mills JJ BMC Med Genet; 2009 Dec; 10():124. PubMed ID: 19954515 [TBL] [Abstract][Full Text] [Related]
11. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Lee SS; Kim KM; Thi-Le H; Yea SS; Cha IJ; Shin JG Ther Drug Monit; 2005 Apr; 27(2):208-10. PubMed ID: 15795654 [TBL] [Abstract][Full Text] [Related]
13. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Martis S; Peter I; Hulot JS; Kornreich R; Desnick RJ; Scott SA Pharmacogenomics J; 2013 Aug; 13(4):369-77. PubMed ID: 22491019 [TBL] [Abstract][Full Text] [Related]
14. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785 [TBL] [Abstract][Full Text] [Related]
15. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495 [TBL] [Abstract][Full Text] [Related]
17. Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran). Hashemi-Soteh SM; Shahabi-Majd N; Gholizadeh AR; Shiran MR Genet Test Mol Biomarkers; 2012 Jul; 16(7):817-21. PubMed ID: 22288731 [TBL] [Abstract][Full Text] [Related]
18. The pharmacogenetics of the response to warfarin in Chinese. Lam MP; Cheung BM Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024 [TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181 [TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]